Copyright
©The Author(s) 2015.
World J Gastrointest Oncol. Jun 15, 2015; 7(6): 47-54
Published online Jun 15, 2015. doi: 10.4251/wjgo.v7.i6.47
Published online Jun 15, 2015. doi: 10.4251/wjgo.v7.i6.47
Table 1 Patient characteristics
| DEBIRITUX | |
| Number of patients | 40 |
| Sex (M-F) | 24-16 |
| Age | 61 (range 47-74) |
| Liver involvement ( ≤ 25%- ≤ 50%) | 18-22 |
| Synchronous/metachronous disease | 0/40 |
| Number of metastases | 3.5 (range 3–9) |
| Largest diameter (cm) | 5 (range 2.5-6) |
| Performance status (0-1 and 2) | 25 and 15 |
| Extrahepatic metastases | 0 |
| Previous CHT (1 line/2 lines for ≤ 12 mo) | 23-17 |
| Types of previous CHT | 23 FOLFOX |
| 11 IFL | |
| 3 FOLFOX + bevacizumab | |
| 3 FU + cetuximab | |
| Weight loss in last 3 mo | 16 (40%) |
| CEA (ng/mL) | 90 (range 7.5-1250) |
| KRas (WT-M) | 24-16 |
| LDH (normal-high) | 32-8 |
| Albumin, g/dL (median) | 4 |
Table 2 Advers events
| Adverse events | n (%) |
| Acne-like skin rash | 5 (50%) |
| Skin fissuring | 3 (30%) |
| Skin dryness | 3 (30%) |
| Hypersensitivity | 3 (30%) |
- Citation: Fiorentini G, Aliberti C, Sarti D, Coschiera P, Tilli M, Mulazzani L, Giordani P, Graziano F, Gonzalez AM, Marcos RG, Mugnoz FG, Cantore M, Ricci S, Catalano V, Mambrini A. Locoregional therapy and systemic cetuximab to treat colorectal liver metastases. World J Gastrointest Oncol 2015; 7(6): 47-54
- URL: https://www.wjgnet.com/1948-5204/full/v7/i6/47.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v7.i6.47